Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Bispecific ADC) Receiving Breakthrough Therapy Designation from the U.S. FDA for the Treatment of Advanced EGFR-Mutant Non-Small Cell Lung Cancer

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Bispecific ADC) Receiving Breakthrough Therapy Designation from the U.S. FDA for the Treatment of Advanced EGFR-Mutant Non-Small Cell Lung Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis